H.C. Wainwright Maintains Myomo(MYO.US) With Buy Rating, Raises Target Price to $9.5
A. G. P. Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $6.75
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating, Announces Target Price $10
Craig-Hallum Maintains Buy on Myomo, Lowers Price Target to $10
Myomo Analyst Ratings
Craig-Hallum Sticks to Their Buy Rating for Myomo (MYO)
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Myomo (MYO) Receives a Buy From Craig-Hallum
Myomo Analyst Ratings
Maxim Group Maintains Myomo(MYO.US) With Buy Rating, Announces Target Price $8
Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)
Citi Initiates Myomo(MYO.US) With Buy Rating, Announces Target Price $9.5
Myomo Price Target Raised to $9.50/Share From $7.50 by HC Wainwright & Co.
Myomo Is Maintained at Buy by HC Wainwright & Co.
Myomo's Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
A. G. P. Maintains Myomo(MYO.US) With Buy Rating, Raises Target Price to $6.75
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating, Announces Target Price $11
Myomo Analyst Ratings
Craig-Hallum Maintains Buy on Myomo, Raises Price Target to $11